Michael Gallagher, MD
Cardiovascular Disease · Troy, MINPI 1407816523
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $175,029 of the $284,398 with a category attached, or 61.5%. Heartflow, Inc. accounts for 98.6% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $107,405, 9.0 times the $11,995 reported in 2019. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 203 payments — averaging $1400.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Heartflow, Inc.$280K
- Siemens Medical Solutions USA, Inc.$2K
- Medtronic$382
- Novartis$291
- Amgen$258
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$246
- plus $1K from 14 others
Across 3 payments — averaging $8483.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Heartflow, Inc.$25K
What the payments were for
- Consulting fees$94,76333%
- Speaking & faculty fees$175,02962%
- Travel & lodging$9,4193%
- Food & beverage$5,1702%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Heartflow, Inc. | 115 | $280,486 |
| Siemens Medical Solutions USA, Inc. | 2 | $1,611 |
| Medtronic(2 entities) | 7 | $382 |
| Novartis | 21 | $291 |
| Amgen | 10 | $258 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $246 |
| Sanofi-aventis U.S. LLC | 8 | $201 |
| Boston Scientific | 7 | $175 |
| Abbott | 1 | $151 |
| E.r. Squibb & Sons, L.L.C. | 2 | $135 |
| Irhythm Technologies, Inc. | 1 | $98 |
| Ablative Solutions, Inc. | 1 | $87 |
| Johnson & Johnson | 5 | $61 |
| Amarin Pharma, Inc. | 4 | $59 |
| Alnylam Pharmaceuticals Inc. | 3 | $47 |
| Boehringer Ingelheim | 2 | $41 |
| Kestra Medical Technology Services, Inc. | 1 | $32 |
| Preventice Services, LLC | 1 | $16 |
| AstraZeneca | 1 | $12 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$268,405
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$151
- ACUSON Origin Diagnostic Ultrasound System$148
- CoreValve Evolut$144
- Repatha$124
- CAMZYOS$121
- PRALUENT$108
- LifeVest$102
How this compares
$284,398 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 392 | $509,057 |
| EntrestoSacubitril/Valsartan | 166 | $235,989 |
| XareltoRivaroxaban | 119 | $162,687 |
| JardianceEmpagliflozin | 76 | $86,439 |
| Repatha SureclickEvolocumab | 39 | $20,759 |
| Metoprolol Succinate | 520 | $11,652 |
| Ranolazine ErRanolazine | 50 | $8,099 |
| Valsartan | 161 | $7,789 |
| Atorvastatin Calcium | 430 | $7,165 |
| Rosuvastatin Calcium | 314 | $6,824 |
| Carvedilol | 468 | $6,596 |
| Praluent PenAlirocumab | 13 | $5,810 |
| Olmesartan Medoxomil | 202 | $5,367 |
| Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med | 76 | $4,946 |
| Ezetimibe | 165 | $4,216 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $11 | $509,057392 claims |
| NovartisEntresto | $291 | $235,989166 claims |
| Johnson & JohnsonXarelto | $61 | $162,687119 claims |
| Boehringer IngelheimJardiance | $41 | $86,43976 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Troy
- Steven AlmanyTroy$471K
- Terry BowersTroy$255K
- Steven AjluniTroy$55K
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- David StroblLansing$445K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.